Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Roche’s Tecentriq recommended for EU approval to treat lung cancer form

Written by: | no-reply@reuters.com | Dated: Friday, July 26th, 2019

 

ZURICH (Reuters) – The European Medicine Agency’s Committee for Medicinal Products for Human Use has recommended EU approval of Roche’s cancer immunotherapy Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer, the Basel company said on Friday.

The EMA also adopted a positive opinion of Tecentriq in combination with chemotherapy as an initial treatment for the most common form of advanced lung cancer – metastatic non-squamous non-small cell lung cancer – Roche said in a separate statement.

 

Reporting by Brenna Hughes Neghaiwi

 

Reuters source:

https://www.reuters.com/article/us-roche-tecentriq/roches-tecentriq-recommended-for-eu-approval-to-treat-lung-cancer-form-idUSKCN1UL1EQ

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom